Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 30  |  Issue : 3  |  Page : 721-726

Study of serum hepcidin in patients with chronic hepatitis C


1 Department of Tropical Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Medical Biochemistry, Faculty of Medicine, Menoufia University, Menoufia, Egypt
3 Department of Tropical Medicine, Tanta Fever Hospital, Tanta, Egypt

Correspondence Address:
Rania R Hamza
Kobry Kohafa, Tanta, Gharbia, 31741
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.218262

Rights and Permissions

Objective The aim of the present work was to study serum hepcidin in patients with chronic hepatitis C (CHC) as an iron homoeostasis-regulating hormone. Background Persistent infection with hepatitis C virus (HCV) is a major cause of chronic liver disease. Many experimental and clinical studies suggest that excessive iron in CHC is a cofactor promoting the progression of liver damage and increasing the risk for fibrosis. Patients and methods In all, 40 patients with CHC (group 1) and 20 healthy individuals (group 2) who served as a control group were included in this study. All patients were subjected to the following: full and detailed history taking, complete clinical examinations, routine laboratory investigations such as complete blood count, liver function tests, prothrombin time, serum creatinine, antinuclear antibody, thyroid-stimulating hormone, α-fetoprotein, viral markers, PCR for hepatitis C, serum hepcidin (ng/ml), serum iron (μg/dl), serum ferritin (ng/ml) and serum total iron-binding capacity (TIBC) (μg/dl), abdominal ultrasound and liver biopsy for CHC patients only for histopathological examination according Metavir scoring. Results Serum hepcidin (ng/ml) was highly significantly lower in CHC patients than in controls (7.95 ± 1.72 and 17.09 ± 1.19, respectively; P < 0.001). Serum iron (μg/dl) was highly significantly lower in CHC patients than in controls (68.34 ± 8.24 and 120.56 ± 10.03, respectively; P < 0.001). Serum ferritin (ng/ml) was significantly higher in CHC patients than in controls (246.28 ± 15.12 and 101.21 ± 11.66, respectively; P < 0.001), and serum TIBC (μg/dl) was significantly higher in CHC patients than in controls (376.75 ± 10.46 and 295.6 ± 7.10, respectively; P < 0.001). Conclusion Hepcidin levels (ng/ml) in patients with CHC were significantly lower than that in HCV-negative individuals. It is an important factor in iron abnormalities and is detected in such cases in which serum iron (μg/dl) levels are significantly low. However, serum ferritin (ng/ml) and serum TIBC (μg/dl) were significantly high in CHC patients compared with HCV-negative individuals.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed881    
    Printed6    
    Emailed0    
    PDF Downloaded90    
    Comments [Add]    

Recommend this journal